Accelerating focus on the patient
16:00 EST 14 Feb 2013 | World Pharma News
With its "crossover year" delivered in 2012 and UCB's new core medicines now driving company growth, UCB's transformation into a biopharma company is complete. UCB is now entering an important new phase of revenue growth with no major patent expiry e..
Original Article: Accelerating focus on the patient
More From BioPortfolio on "Accelerating focus on the patient"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
